Press Releases

INOVIO Announces Positive Results from REVEAL 1, a Phase 3 Pivotal Trial Evaluating VGX-3100, its DNA-based HPV Immunotherapy for the Treatment of High-grade Precancerous Cervical Dysplasia Caused by HPV-16 and/or HPV-18

Posted on March 1, 2021

INOVIO and QIAGEN expand collaboration to develop next generation sequencing (NGS) companion diagnostic for INOVIO’s VGX-3100 for advanced cervical dysplasia

Posted on February 24, 2021

INOVIO Announces First Subject Dosed in Phase 1B Clinical Trial for its DNA Vaccine Against Lassa Fever, INO-4500, in West Africa

Posted on February 23, 2021

INOVIO to Report Fourth Quarter and Full Year 2020 Financial Results on March 1, 2021

Posted on February 16, 2021

INOVIO Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

Posted on January 25, 2021

INOVIO Announces Pricing of Public Offering of Common Stock

Posted on January 20, 2021

INOVIO Announces Proposed Public Offering of Common Stock

Posted on January 20, 2021

INOVIO’s VGX-3100 Demonstrates Positive Phase 2 Efficacy In Treatment of Precancerous Vulvar Dysplasia Caused by HPV-16/18

Posted on January 6, 2021

INOVIO and Advaccine Announce Exclusive Partnership To Commercialize COVID-19 DNA Vaccine Candidate, INO-4800, in Greater China

Posted on January 4, 2021

INOVIO Announces Publication of Phase 1 Data from its COVID-19 DNA Vaccine Candidate, INO-4800 in The Lancet’s EClinicalMedicine

Posted on December 24, 2020

© Copyright 2025 INOVIO Pharmaceuticals. All rights reserved.